Our MASCC study groups have released several new sets of guidelines in 2024:
- The Antiemetics Study Group in collaboration with ESMO has updated the MASCC/ESMO Antiemetic Guidelines, including:
- Emetic classification of antineoplastic agents
- Highly emetic chemotherapy
- Moderately emetic chemotherapy
- Low or minimally emetic chemotherapy
- Multiple-day, high-dose chemotherapy, refractory, break-through nausea and vomiting
- CAMs and non-pharmacological interventions
- Radiotherapy-induced nausea and vomiting
2. The Oncodermatology and Survivorship Study Groups have created new MASCC clinical practice guidance for the prevention of breast cancer-related arm lymphoedema (BCRAL) based on international Delphi consensus-based recommendations.
3. The Palliative Care Study Group has published an expert opinion/guidance on the use of clinically assisted hydration in patients with advanced cancer.
